SLU-PP-332
A pan-agonist of estrogen-related receptors (ERRα/β/γ) that induces the aerobic exercise gene program and increases energy expenditure.
Also known as: ERR Agonist, Exercise in a Pill
Available on Forge Amino
SLU-PP-332 — independently lab tested, 99%+ purity, QR-linked COA.
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
Binds ligand-binding domain of ERRα, promoting interaction with PGC-1α. Triggers acute aerobic exercise genetic program with increased type IIa oxidative muscle fibers, mitochondrial biogenesis, and energy expenditure.
Key Benefits
- ✓Induces exercise gene program without activity
- ✓Increased energy expenditure
- ✓Enhanced fatty acid oxidation
- ✓Improved insulin sensitivity
- ✓Increased type IIa oxidative muscle
Dosing Protocols
Beginner / Intermediate
Dose
250 mcg
Frequency
Every other day oral (AM)
Cycle Length
4 weeks
Notes
Estimated from preclinical data; no human dosing established
Advanced
Dose
250 mcg
Frequency
Once daily oral (AM)
Cycle Length
8-12 weeks
Notes
Least-studied compound; dosing is anecdotal and experimental
Side Effects & Safety
Common Side Effects
- Appetite modulation
- Initial energy dysregulation
- Uncertain cardiovascular effects at higher doses
- Unknown off-target ERR effects
Contraindications
- Pregnancy and breastfeeding
- Uncontrolled cardiac disease
- Cancer history (unclear risk)
- Severe liver disease
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Activate endurance pathways without training: SLU-PP-332 ignites ERR-driven metabolic remodeling.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.